Text Size
7 studies found for:    12826635 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: THALIDOMIDE;   Drug: BORTEZOMIB
2 Completed Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Melphalan;   Drug: Prednisone
3 Completed GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
Condition: Multiple Myeloma
Interventions: Drug: Melphalan/Prednisone/Velcade;   Drug: Thalidomide/Prednisone/Velcade
4 Completed GEM05 for Patients With Multiple Myeloma Under 65 Years
Condition: Multiple Myeloma
Interventions: Drug: VBMCP/VBAD/Velcade;   Drug: Thalidomide/Dexamethasone;   Drug: Velcade/Thalidomide/Dexamethasone
5 Completed Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: Melphalan, Bortezomib
6 Completed VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Velcade/Dexamethasone
7 Completed A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Bortezomib and Tositumomab I-131
To Top

† Indicates status has not been verified in more than two years